Keyword Analysis & Research: biogen pipeline
Keyword Research: People who searched biogen pipeline also searched
Search Results related to biogen pipeline on Search Engine
-
Pipeline | Biogen
https://www.biogen.com/science-and-innovation/pipeline.html
WEBBreaking New Ground With Science. With a strong focus on difficult-to-treat diseases, our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients and protect public health.
DA: 29 PA: 1 MOZ Rank: 52
-
Clinical Trials | Biogen
https://www.biogen.com/science-and-innovation/clinical-trials.html
WEBView our current pipeline to learn more about clinical trials for specific conditions. See detailed information on currently enrolling clinical trials for Biogen investigational and marketed therapies on clinicaltrials.gov
DA: 79 PA: 9 MOZ Rank: 29
-
Home | Biogen
https://www.biogen.com/
WEBBiogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.
DA: 58 PA: 46 MOZ Rank: 38
-
New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 …
https://investors.biogen.com/news-releases/news-release-details/new-data-presented-adpdtm-2023-show-biogens-biib080-mapt-aso
WEBMar 29, 2023 · Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialized immunology and rare diseases and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.
DA: 77 PA: 53 MOZ Rank: 39
-
Biogen R&D Day to Provide Overview of Diversified Pipeline and
https://investors.biogen.com/news-releases/news-release-details/biogen-rd-day-provide-overview-diversified-pipeline-and
WEBCAMBRIDGE, Mass., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will hold a virtual Investor R&D Day today, providing a comprehensive overview of the company’s diversified pipeline in neuroscience. Biogen plans to advance innovative therapies for patients through the work of its world-class researchers and the strength of …
DA: 90 PA: 57 MOZ Rank: 29
-
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a
https://www.globenewswire.com/news-release/2023/09/29/2752273/0/en/FDA-Approves-Biogen-s-TOFIDENCE-tocilizumab-bavi-a-Biosimilar-Referencing-ACTEMRA.html
WEBSep 29, 2023 · Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialized immunology and rare diseases and remains acutely focused on its purpose of serving ...
DA: 51 PA: 72 MOZ Rank: 40
-
Multiple Sclerosis | Biogen
https://www.biogen.com/disease-areas/multiple-sclerosis.html
WEBAs pioneers in neuroscience, Biogen has an innovative therapeutic pipeline that aims to reverse disability, repair damage, and address other remaining unmet needs in MS, with the goal of significantly altering the course of MS and preventing disease development and disability progression.
DA: 72 PA: 68 MOZ Rank: 89
-
2021 YEAR IN REVIEW - Biogen
https://www.biogen.com/content/dam/corporate/en_us/YIR-2021/Biogen-YearInReview-2021.pdf
WEB2021 Pipeline Highlights We received significant data readouts during the year in a number of promising areas. We see high potential for zuranolone (BIIB125), an investigational two-week, once-daily drug in development for the potential treatment of major depressive disorder (MDD) and postpartum depression (PPD), to
DA: 48 PA: 45 MOZ Rank: 16
-
Biogen R&D Day to Provide Overview of Diversified Pipeline and
https://finance.yahoo.com/news/biogen-r-d-day-overview-123000663.html
WEBSep 21, 2021 · Biogen will present an overview of its Alzheimer’s disease pipeline with the recent FDA-approved ADUHELM serving as the foundation of a multi-target, multi-modality Alzheimer’s disease franchise.
DA: 36 PA: 13 MOZ Rank: 7
-
Busy with 3 program launches this year, Biogen trims pipeline
https://www.fiercebiotech.com/biotech/busy-3-program-launches-year-biogen-trims-pipeline
WEBApr 25, 2023 · Biogen announced a pipeline reprioritization Tuesday in its first-quarter earnings release. On the chopping block is BIIB093, a phase 3 asset for large hemispheric infarction.
DA: 30 PA: 8 MOZ Rank: 25
